Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.58 |
| ▸ | MMP2 | P08253 | 9/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.54 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP1 | P03956 | 4/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.49 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 4/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP16 | P51512 | 1/20 | 0.44 |
| ▸ | TARS1 | P26639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798738 | 1.00 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1801383 | 0.91 | ADAMTS7 (0.50) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1801386 | 0.91 | ADAMTS7 (0.50) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL4371646 | 0.88 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL3876756 | 0.88 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798488 | 0.84 | ADAMTS7 (0.54) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798485 | 0.84 | ADAMTS7 (0.54) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL3872719 | 0.84 | MMP13 (0.56) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL3874462 | 0.82 | MMP13 (0.54) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798436 | 0.81 | ADAMTS7 (0.46) | MMP13ADAMTS5ADAMTS7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | claimed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | claimed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | MMP13 62/4885MMP2 133/4885MMP9 35/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | MMP13 386/4885MMP2 223/4885MMP9 97/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | MMP13 97/4885MMP2 203/4885MMP9 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.